Association between Characterizations of Bone Marrow Mesenchymal Stem Cells, Ejection Faction and Hospitalization Period in Patients with Severe Left Ventricular Dysfunction after Off-Pump Bypass Surgery
Archives of Medical Laboratory Sciences,
Vol. 5 No. 4 (2019),
23 September 2019
,
Page 30-36
https://doi.org/10.22037/amls.v5i4.31296
Abstract
Background and Aim: Severe left ventricular dysfunction patients with ejection fraction ≤ 30% are at a higher risk for complications and mortality than patients with ejection fraction >30%. The death of cardio-myocytes at injured regions leads to myocardium dysfunction. Bone marrow-derived mesenchymal stem cells are undifferentiated cells that have been used for the regeneration of damaged cardio-myocytes. Due to the inherent capability of mesenchymal stem cells to improve cardiac functions, in this research, our objective was to explore the possible association of the mesenchymal stem cells proliferation rate with Coronary Artery Bypass Grafting outcomes in patients with severe left ventricular dysfunction after off-pump Coronary Artery Bypass Grafting. Methods: For investigating the possible association of mesenchymal stem cells proliferation with Coronary Artery Bypass Grafting outcomes (ejection fraction, hypertension risk, and the time of hospital stay), we collected bone marrow samples from 30 patients (18 men and 12 women) who underwent off-pump Coronary Artery Bypass Grafting at Afshar Hospital and Seyed Al-Shohada Hospital (Yazd, Iran). Mesenchymal stem cells were isolated and cultured; then, cells were counted after 4, 7, and 14 days using trypan-blue color, and doubling times were calculated. Results: There was an association between doubling time and ejection fraction after surgery. Ejection fraction in postoperative patients increased, but this association was not significant. Also, our study showed that the risk of hypertension is equal in male and female patients. There were no significant differences in mesenchymal stem cells doubling time with hypertension and the time of hospital stay in the ICU. Conclusion: Based on this study, we concluded that there was no significant relationship between the rate of mesenchymal stem cell proliferation and Coronary Artery Bypass Grafting outcomes in patients with severe left ventricular dysfunction.
*Corresponding Author: Zakieh Sadat Sheikhalishahi; Email: z.sheikhalishahi@gmail.com
Please cite this article as: Esmailidehaj M, Mirhosseini SJ, Sheikhalishahi ZS. Association between Characterizations of Bone Marrow Mesenchymal Stem Cells, Ejection Faction and Hospitalization Period in Patients with Severe Left Ventricular Dysfunction after Off-Pump Bypass Surgery. Arch Med Lab Sci. 2019;5(4):30-36. https://doi.org/10.22037/amls.v5i4.31296
- Severe Left Ventricular Dysfunction
- Mesenchymal Stem Cell
- Doubling Time
- Ejection Fraction
How to Cite
References
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. New England Journal of Medicine. 2016; 374(16):1511-20.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005; 18(12):1440-63.
Hafez P, Jose S, Chowdhury SR, Ng MH, Ruszymah B, Abdul Rahman Mohd R. Cardiomyogenic differentiation of human sternal bone marrow mesenchymal stem cells using a combination of basic fibroblast growth factor and hydrocortisone. Cell biology international. 2016; 40(1):55-64.
Ma Z, Yang H, Liu H, Xu M, Runyan RB, Eisenberg CA, et al. Mesenchymal stem cell-cardiomyocyte interactions under defined contact modes on laser-patterned biochips. PLoS One. 2013; 8(2).
Hong TH, Ha YJ, Jeong DS, Kim WS, Lee YT. Graft strategy for coronary artery bypass grafting in patients with severe left ventricular dysfunction. The Korean Journal of thoracic and cardiovascular surgery. 2019; 52(1):16.
Yoo JS, Kim JB, Jung S-H, Choo SJ, Chung CH, Lee JW. Coronary artery bypass grafting in patients with left ventricular dysfunction: predictors of long-term survival and impact of surgical strategies. International journal of cardiology. 2013; 168(6):5316-22.
Kaźmierski Ł, Bajek A, Dębski R, Gagat M, Grzanka A, Bodnar M, et al. Can bone marrow mesenchymal stem cells regenerate the myocardium? Medical Research Journal. 2018; 3(3):153-8.
Tachibana A, Santoso MR, Mahmoudi M, Shukla P, Wang L, Bennett M, et al. Paracrine effects of the pluripotent stem cell-derived cardiac myocytes salvage the injured myocardium. Circulation research. 2017; 121(6):e22-e36.
Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA, et al. Interaction of the synthesized anticancer compound of the methyl-glycine 1, 10-phenanthroline platinum nitrate with human serum albumin and human hemoglobin proteins by spectroscopy methods and molecular docking. Journal of the Iranian Chemical Society. 2020:1-14.
Shafei AES, Ali MA, Ghanem HG, Shehata AI, Abdelgawad AA, Handal HR, et al. Mesenchymal stem cell therapy: A promising cell‐based therapy for the treatment of myocardial infarction. The journal of gene medicine. 2017; 19(12):e2995.
Szaraz P, Gratch YS, Iqbal F, Librach CL. In vitro differentiation of human mesenchymal stem cells into functional cardiomyocyte-like cells. JoVE (Journal of Visualized Experiments). 2017(126):e55757.
Chauveau S, Anyukhovsky EP, Ben-Ari M, Naor S, Jiang Y-P, Danilo Jr P, et al. Induced pluripotent stem cell-derived cardiomyocytes provide in vivo biological pacemaker function. Circulation: Arrhythmia and Electrophysiology. 2017; 10(5):e004508.
Abbasi M, Abazari OO. Probing the Biological evaluations of a newly designed Palladium (II) complex using spectroscopic and theoretical approaches: Human Hemoglobin as a Target. Archives of Medical Laboratory Sciences. 2018; 3(3).
Konoplyannikov M, Kotova S, Baklaushev V, Konoplyannikov A, Kalsin V, Timashev P, et al. Mesenchymal stem cell therapy for ischemic heart disease: Advances and challenges. Current pharmaceutical design. 2018; 24(26):3132-42.
Pieri M, Belletti A, Monaco F, Pisano A, Musu M, Dalessandro V, et al. Outcome of cardiac surgery in patients with low preoperative ejection fraction. BMC anesthesiology. 2016; 16(1):97.
Terzic A, Behfar A. Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends in cardiovascular medicine. 2016; 26(5):395-404.
Fisher SA, Doree C, Mathur A, Taggart DP, Martin‐Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews. 2016(12).
Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin on Transforming Growth Factor-β-mediated Non-Smad Signaling Pathway, Oxidative Stress, and Pro‐inflammatory Cytokines Production with Human Vascular Smooth Muscle Cells. Iranian Journal of Allergy, Asthma, and Immunology. 2019:1-10.
Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. International journal of molecular sciences. 2016; 17(7):1164.
Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxaliplatin as a chemotherapeutic drug on the function and structure of bovine liver catalase. Journal of Biomolecular Structure and Dynamics. 2020; 38(2):609-15.
Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA. Probing the biological evaluations of a newly designed Pt (II) complex using spectroscopic and theoretical approaches: Human hemoglobin as a target. Journal of Biomolecular Structure and Dynamics. 2016; 34(5):1123-31.
Tsai T-L, Li W-J. Identification of bone marrow-derived soluble factors regulating human mesenchymal stem cells for bone regeneration. Stem cell reports. 2017; 8(2):387-400.
Ayatollahi M, Geramizadeh B, Zakerinia M, Ramzi M, Yaghobi R, Hadadi P, et al. Human bone marrow-derived mesenchymal stem cell: A source for cell-based therapy. International journal of organ transplantation medicine. 2012; 3(1):32.
Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxaliplatin as a chemotherapeutic drug on the function and structure of bovine liver catalase. Journal of Biomolecular Structure and Dynamics. 2019:1-7.
Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation. 2006; 114(1_supplement): I-181-I-5.
- Abstract Viewed: 213 times
- PDF Downloaded: 145 times